Icon

Vyndamax - (61mg; Capsule)

Tafamidis FoldRx Pharma
61mg; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
None None
VYNDAMAX is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization
Yes
****** ******** ****** ****** ** ****. *** ******* ** *** **, ****. ****** ****** (******) *** *** *** ** *** **** *** *** ********* *****. ********* ** ******'* ****** ******, ***** ******* ****** ******* ** **** (**** ********* ***). *****, ***** (******) *** ****** (******) **** **** *********.
Vyndamax Patent 1 Patent 2 Patent 3
****** ****** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
***** *** ********* *** ********* **** ** *** **, ****
****** ****** *** ********* *** ********* **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** ****** *** / ********* *** **, **** ******* **** *** ****** *** ****
***** *** / ********* *** **, **** ******* **** *** ****** *** ****
****** ****** *** / ********* *** **, **** ******* **** *** ****** *** ****
  1. *** *, **** : * ****-** ** ***** *** ***** *** ***** *** *********.
  2. *** **, **** : ****** ****** ******** ****** ** ***** **** ** ******.
  3. *** **, **** : ***** ******** ****** ** ***** **** ** ******.
  4. *** **, **** : ****** ******** ****** ** ***** **** ** ******.
  5. *** **, **** : ****** **** ****** ****** **** ************ ** ******* ’***, ’***, *** ’***.
  6. *** **, **** : ****** **** ***** **** ************ ** ****** ’***.
  7. *** **, **** : ****** **** ****** **** ************ ** ****** ’***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.